BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/15/2016 4:06:00 PM | Browse: 507 | Download: 348
Publication Name World Journal of Hepatology
Manuscript ID 25575
Country of Manuscript Source France
2016-03-15 11:21
Peer-Review Started
2016-03-18 09:24
To Make the First Decision
2016-04-18 19:35
Return for Revision
2016-04-20 18:51
Second Decision
2016-10-21 10:21
Accepted by Journal Editor-in-Chief
2016-10-22 05:10
Accepted by Company Editor-in-Chief
2016-11-02 15:53
Articles in Press
2016-11-02 15:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-12-12 09:59
Publish the Manuscript Online
2016-12-15 16:07
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Jean-Luc Raoul, Xavier Adhoute, Marine Gilabert and Julien Edeline
Funding Agency and Grant Number
Correspondence To Dr. Jean-Luc Raoul, Professor, Depart­ment of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273 Marseille, France. raouljl@ipc.unicancer.fr
Keywords Tumor evaluation; Response evaluation criteria in solid tumors; Sorafenib; Hepatocellular carcinoma; Modified response evaluation criteria in solid tumors
Core Tip The response rate of sorafenib in hepato-cellular carcinoma is low using standard parameters and is better assessed using new criteria based on tumor vascularization (European Association of the Study of the Liver criteria, modified response evaluation criteria in solid tumors). In case of minor progression, if sorafenib is well tolerated, knowing the predictors of post-progression survival will be of value in deciding whether to continue or stop sorafenib.
Publish Date 2016-12-15 16:07
Citation Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol 2016; 8(35): 1541-1546
Url http://www.wjgnet.com/1948-5182/full/v8/i35/1541.htm
DOI http://dx.doi.org/10.4254/wjh.v8.i35.1541
Full Article (PDF) WJH-8-1541.pdf
Full Article (Word) WJH-8-1541.doc
Revised Manuscript 25575-Review.docx
Peer-review Report 25575-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 25575-Journal editor-in-chief review report.pdf
Answering Reviewers 25575-Answering reviewers.pdf
Scientific Misconduct Check 25575-Scientific misconduct check.pdf
Scientific Editor Work List 25575-Scientific editor work list.pdf
Audio Core Tip 25575-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 25575-Conflict-of-interest statement.pdf
Copyright License Agreement 25575-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 25575-Language certificate.pdf